Innovatus Imaging is Opening up a Virtual Tour of Its Proprietary Technology Developed Over Nearly 40 Years

September 1, 2020

Innovatus Imaging is opening up a virtual tour of its proprietary technology developed over nearly 40 years.

Innovatus Imaging notes touring the company’s Centers of Excellence for Design, Engineering, and Manufacturing, and Ultrasound Probe Repair, even virtually, Healthcare Technology Management experts will be able to identify the processes and technology behind sustainable repairs that result in enhanced device lifecycles, lower cost of ownership, and higher ROI’s.

“Many people don’t realize that Innovatus Imaging’s heritage lies with the industry’s most prolific pioneers,” said Matt Tomory, Vice President of Sales and Marketing for Innovatus Imaging. “Our leaders developed the technology and the processes for holistic repairs and testing which today are still driving high efficiencies, best-in-class quality, and performs as intended by the OEM.”

The technology behind Innovatus Imaging’s industry-leading record for accurate, sustainable ultrasound probe repairs is showcased in an 8-minute virtual tour of the Centers of Excellence in Denver, CO, and Tulsa, OK.  The video provides a glimpse of what to look for in repair processes that are proven to help save money from fewer repairs and device longevity.

The tour video, titled “Ultrasound Transducer Longevity, Performance and ROI Come Down to One Critical Difference: Technology,“ can be found here.

Innovatus Imaging was formed in 2017 when Bayer Multi-Vendor Service, Wetsco, and MD MedTech merged to form a national presence with three Centers of Excellence for medical device Design, Engineering, and Manufacturing; Ultrasound Probe Repair; and MRI Coil Repair. Within three years of operation, Innovatus Imaging quickly became the partner of choice for the industry’s largest resellers of repair services as well as major hospitals and healthcare systems.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”